Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elenestinib (Primary)
Indications Systemic mastocytosis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms HARBOR
Sponsors Blueprint Medicines

Most Recent Events

01 May 2025 According to a Blueprint Medicines media release, company is planning to activate sites and drive enrollment in HARBOR trial of elenestinib in 2025
30 Apr 2025 Timeframe of primary endpoint changed
30 Apr 2025 Planned number of patients changed from 463 to 534.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com